TYK MEDICINES-B(02410.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 24.9 million, loss narrowed by 77.81% YoY

NewTimeSpace News: August 17, 2026, TYK MEDICINES-B(02410.HK) released its Interim Report for the period ended December 31, 2026; Net Profit stood at loss of CNY 26.88 million, loss narrowed by 76.43% YoY; Profit Attributable to Shareholders stood at loss of CNY 24.9 million, loss narrowed by 77.81% YoY; Basic Earnings Per Share (EPS) stood at loss of CNY cents 7.

In terms of profitability, TYK MEDICINES-B net profit changed from loss of CNY 114.07 million in the same period last year to loss of CNY 26.88 million in the current period, increased by CNY 87.18 million.

In terms of earnings quality, TYK MEDICINES-B Operating Profit changed from loss of CNY 106.72 million in the same period last year to loss of CNY 15.22 million in the current period, increased by CNY 91.5 million.

In terms of financial soundness, TYK MEDICINES-B Debt-to-Asset Ratio changed from 54.87% in the same period last year to 66.07% in the current period, increased by 11.2 percentage points; Total Equity changed from CNY 358.497 million in the same period last year to CNY 260.764 million in the current period, decreased by CNY 97.73 million; Current Liabilities changed from CNY 259.33 million in the same period last year to CNY 252.68 million in the current period, decreased by CNY 6.65 million.

In terms of R&D investment focus, TYK MEDICINES-B R&D Expenses changed from CNY 88.76 million in the same period last year to CNY 94.94 million in the current period, increased by CNY 6.19 million.

By the close of trading on August 17, 2026, TYK MEDICINES-B(02410) saw a gain of 0.37% in its share price, closing at HKD 6.75. The full-day turnover stood at HKD 13.21 million, with the latest market capitalization at HKD 2.57 billion.

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.